Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)

SHA:600566 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	5,901	6,219	8,017	9,655	8,996	7,631
Revenue Growth	-17.35%	-22.43%	-16.96%	7.32%	17.90%	23.77%
Gross Profit Gross Profit Growth	4,723	4,909	6,350	7,871	7,459	6,354
Operating Income Operating Income Growth	1,810	1,855	2,427	2,884	2,254	1,671
Net Income Net Income Growth	1,738	1,778	2,532	2,823	2,171	1,719
Earnings Per Share EPS Growth	1.89	1.93	2.76	3.08	2.39	1.91
EPS Growth	-18.50%	-30.07%	-10.39%	28.87%	25.13%	24.84%

Revenue by Segment

Chart

Fiscal Year	FY 2025
Period Ending	Dec 31, 2025
Clearing Heat and Detoxifying Clearing Heat and Detoxifying Growth	1,985
Digestive Digestive Growth	956.02
Pediatrics Pediatrics Growth	1,654
Breathing Breathing Growth	467.04
Cardiovascular Type Cardiovascular Type Growth	60.79
Gynecology Gynecology Growth	30.25
Other Other Growth	797.53
Commercial Commercial Growth	254.31
Total Total Growth	6,205

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	12,576	11,705	11,830	10,916	7,863	5,494
Total Debt Total Debt Growth	1,063	719.03	838.5	1,090	400.65	630.12
Net Cash (Debt) Net Cash Growth	11,513	10,986	10,992	9,826	7,463	4,864
Net Cash Growth	-3.17%	-0.06%	11.86%	31.67%	53.43%	34.56%
Net Cash Per Share Net Cash Per Share Growth	12.52	11.93	11.98	10.72	8.22	5.40

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	1,285	1,198	2,176	3,464	2,621	1,894
Capital Expenditures CapEx Growth	-263.99	-95.86	-174.34	-301.64	-243.66	-248.32
Free Cash Flow Free Cash Flow Growth	1,021	1,102	2,002	3,162	2,377	1,646
Free Cash Flow Growth	-32.76%	-44.94%	-36.69%	33.03%	44.42%	21.74%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	80.04%	78.95%	79.21%	81.52%	82.91%	83.27%
Operating Margin	30.68%	29.82%	30.27%	29.87%	25.05%	21.89%
Pretax Margin	35.96%	34.77%	37.15%	34.15%	27.88%	25.56%
Profit Margin	29.45%	28.59%	31.58%	29.24%	24.13%	22.53%
FCF Margin	17.30%	17.73%	24.97%	32.76%	26.42%	21.57%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 10, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	1.740	1.740	2.090	1.300	0.880	0.680
Dividend Per Share Growth	-16.75%	-16.75%	60.77%	47.73%	29.41%	51.11%
Dividend Yield	6.72%	7.08%	8.29%	4.95%	3.99%	3.05%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 10, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	13.70	13.63	10.59	10.26	11.56	14.64
Forward PE	-	10.76	8.82	11.02	11.16	13.64
P/FCF Ratio	23.38	21.98	13.39	9.16	10.56	15.29
PS Ratio	4.04	3.90	3.34	3.00	2.79	3.30

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 6, 2026

Data Sources Report a data error